Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Read more about Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Read more about Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) Read more about Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery Read more about Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
Safety Study of SEA-CD40 in Cancer Patients Read more about Safety Study of SEA-CD40 in Cancer Patients
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies Read more about Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors Read more about Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome (DM-CHOC-PEN) in Patients With Brain Tumors
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors Read more about PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Read more about HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Read more about Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV